The Science Behind the New Era in Preventive Treatment of Migraine

Migraine Resources published on October 15, 2018
Andrew C. Charles, MD
Professor of Neurology
UCLA School of Medicine
Los Angeles, California
Migraine is a complicated and heterogenous disabling headache disorder. Studies have shown new evidence that calcitonin gene-related peptide (CGRP) is an important target for therapies designed to treat migraine. During a satellite symposium conducted at this year’s American Headache Society meeting and hosted by Emerging Solutions in Pain, Dr. Andrew Charles discussed the role of CGRP and how it differs from other neurotransmitters that, up until this time, have been the primary target for most agents used today to treat migraine headaches. Several CGRP targeted therapies have either been approved by the FDA as treatment for migraine or are currently being investigated in clinical trials.

Download Slides
Provided by MediCom Worldwide, Inc.
Supported by an educational grant from Teva Pharmaceuticals
Last modified: December 10, 2019